Trial · NCT01299272
A Study in Prevention of Re-emergence of Depression Symptoms
NCT01299272, Phase 3, Completed, Eli Lilly and Company; results first posted 2018-04-17
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. A Study in Prevention of Re-emergence of Depression Symptoms. Trials, record NCT01299272. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01299272
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study in Prevention of Re-emergence of Depression Symptoms
- NCT number
- NCT01299272
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 1,249 participants, actual
- Lead sponsor
- Eli Lilly and Company
- Conditions
- Major Depressive Disorder
- Interventions
- LY2216684, Placebo, SSRI
- First posted
- 2011-02-18
- Last updated
- 2018-04-17
- Results first posted
- 2018-04-17
Source ClinicalTrials.gov
Registered outcomes29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants Who Meet Criteria for Re-emergence of Depressive Symptoms Estimated by Kaplan-Meier Product Limit Method (Double-blind Randomized Withdrawal Period) | Randomization up to 44 weeks | Participants meeting any of the following criteria were determined as having major depressive disorder symptom re-emergence: 1) a Montgomery-Asberg Depression Rating Scale (MADRS) total score greater ≥14 or a Clinical Global Impressions of Severity (CGI-S) increase of 2 or more points from Week 18 at 2 consecutive visits or 2) discontinuation due to lack of efficacy/worsening of depression/suicidality. Time from randomization to the first visit at which the participant met the reemergence criteria was calculated. The percentage of participants who meet criteria was estimated using the Kaplan-Meier product limit method. The MADRS is a rating scale for severity of depressive mood symptoms and has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity) to 60 (high severity). CGI-S measures severity of depression at the time of assessment compared with the start of treatment. Scores range from 1 (normal, not at all ill) to 7 (extremely ill). |
| Secondary | Percentage of Participants With Re-emergence of Depressive Symptoms (Double-blind Randomized Withdrawal Period) | Week 44 | Participants meeting any of the following criteria were determined as having major depressive disorder symptom re-emergence: 1) a Montgomery-Asberg Depression Rating Scale (MADRS) total score greater ≥14 or a Clinical Global Impressions of Severity (CGI-S) increase of 2 or more points from Week 18 at 2 consecutive visits or 2) discontinuation due to lack of efficacy/worsening of depression/suicidality. The percentage of participants with re-emergence of depressive symptoms was calculated by dividing the number of participants who meet any of the criteria by the total number of participants analyzed, multiplied by 100. The MADRS is a rating scale for severity of depressive mood symptoms and has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity) to 60 (high severity). CGI-S measures severity of depression at the time of assessment compared with the start of treatment. Scores range from 1 (normal, not at all ill) to 7 (extremely ill). |
| Secondary | Change From Randomization in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Item Scores at Week 44 (Double-blind Randomized Withdrawal Period) | Randomization, Week 44 | Montgomery-Asberg Depression Rating Scale (MADRS) is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist (sadness \[apparent\], sadness \[reported\], inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts). Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) means were calculated using a mixed model repeated measures (MMRM) analysis which includes terms for the fixed categorical effects of treatment, country, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline MADRS total score (individual item score) and baseline MADRS total score (individual item score)-by-visit interaction. |
| Secondary | Change From Randomization in the Hospital Anxiety and Depression Scale (HADS) Depression and Anxiety Subscale Scores at Week 44 (Double-blind Randomized Withdrawal Period) | Randomization, Week 44 | The Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item is rated on a 4-point scale (0-3), giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a 'significant' case of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7 represent 'normal'. Least Squares (LS) means were calculated using a mixed model repeated measures (MMRM) analysis which included terms for the fixed categorical effects of treatment, country, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline subscale score and baseline subscale score-by-visit interaction. |
| Secondary | Change From Randomization in the Clinical Global Impression of Severity (CGI-S) Scores at Week 44 (Double-blind Randomized Withdrawal Period) | Randomization, Week 44 | The Clinical Global Impression of Severity (CGI-S) instrument is used to record the severity of mental illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) means were calculated using a mixed model repeated measures (MMRM) analysis which included terms for the fixed categorical effects of treatment, country, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline CGI-S score and baseline CGI-S score-by-visit interaction. |
| Secondary | Change From Randomization in the Fatigue Associated With Depression (FAsD) Average Score, Experience Subscale Score, and Impact Subscale Score at Week 44 (Double-blind Randomized Withdrawal Period) | Randomization, Week 44 | The FAsD is a 13-item participant-rated scale. Items 1-6 ask how often participants experience different aspects of fatigue with responses from 1 (never) to 5 (always). Items 7-13 ask how often fatigue impacts various aspects of the participant's lives with responses from 1 (not at all) to 5 (very much). The experience subscale score is derived by taking the mean of Items 1-6. The impact subscale score is derived by taking the mean of applicable Items 7-13. The average score is the mean of applicable Items 1-13. Item 12 applies only to participants with a spouse or significant other and Item 13 applies to participants who had a job or who went to school. Least Squares (LS) means were calculated using a mixed model repeated measures (MMRM) analysis which included terms for the fixed categorical effects of treatment, country, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline score and baseline score-by-visit interaction. |
| Secondary | Change From Randomization in the Sheehan Disability Scale (SDS) Items at Week 44 (Double-blind Randomized Withdrawal Period) | Randomization, Week 44 | The Sheehan Disability Scale (SDS) is completed by the participant and used to assess the effect of the participant's symptoms on their work (work/school impairment score), social life (social life/leisure activities impairment score), and family life (family life/home responsibilities impairment score). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. Least Squares (LS) means were calculated using a mixed model repeated measures (MMRM) analysis which included terms for the fixed categorical effects of treatment, country, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline score and baseline score-by-visit interaction |
| Secondary | Change From Randomization in the EuroQol Questionnaire-5 Dimension (EQ-5D) Index Scores, Visual Analog Scale up to Week 44 (Double-blind Randomized Withdrawal Period) | Randomization, up to Week 44 | The EQ-5D, a health-related, quality-of-life instrument, contains 2 parts: a health status profile and a visual analog scale (VAS). The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale (no problem, some problems, and major problems). These dimensions are converted into weighted health-state index scores according to United States (US) and United Kingdom (UK) population-based algorithms. The US and UK based index scores range from -0.11 to 1.0 (where a score of 1.0 indicates perfect health) and from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension), respectively. The VAS consists of participants rating their current health state from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) model with main effects of treatment, country, and baseline score. |
| Secondary | Number of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) (Double-blind Randomized Withdrawal Period) | Randomization through Week 44 | The Columbia-Suicide Severity Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation is defined as a "yes" answer to any 1 of 5 suicidal ideation questions, which includes a wish to be dead and 4 different categories of active suicidal ideation. Suicidal behavior is defined as a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation and behavior are defined as treatment-emergent (TE) if not present during the period up through randomization. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Event module. |
| Secondary | Change From Randomization in the Arizona Sexual Experiences (ASEX) Questionnaire at Week 44 (Double-blind Randomized Withdrawal Period) | Randomization, Week 44 | Arizona Sexual Experiences (ASEX) Questionnaire is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each item is rated from 1 (extremely) to 6 (no/never). Possible total scores ranged from 5 to 30, with the higher scores indicating more sexual dysfunction. Least Squares (LS) means were calculated using a mixed model repeated measures (MMRM) analysis which included terms for the fixed categorical effects of treatment, country, visit, treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline ASEX total score and baseline ASEX total score-by-visit interaction. |
1 to 10 of 29Source ClinicalTrials.gov
See all 29 registered outcomesOutcomes29
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants Who Meet Criteria for Re-emergence of Depressive Symptoms Estimated by Kaplan-Meier Product Limit Method (Double-blind Randomized Withdrawal Period) | Randomization up to 44 weeks | All randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Re-emergence of Depressive Symptoms (Double-blind Randomized Withdrawal Period) | Week 44 | All randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Change From Randomization in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Item Scores at Week 44 (Double-blind Randomized Withdrawal Period) | Randomization, Week 44 | All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value. | units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Randomization in the Hospital Anxiety and Depression Scale (HADS) Depression and Anxiety Subscale Scores at Week 44 (Double-blind Randomized Withdrawal Period) | Randomization, Week 44 | All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value. | units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Randomization in the Clinical Global Impression of Severity (CGI-S) Scores at Week 44 (Double-blind Randomized Withdrawal Period) | Randomization, Week 44 | All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value. | units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Randomization in the Fatigue Associated With Depression (FAsD) Average Score, Experience Subscale Score, and Impact Subscale Score at Week 44 (Double-blind Randomized Withdrawal Period) | Randomization, Week 44 | All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value. | units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Randomization in the Sheehan Disability Scale (SDS) Items at Week 44 (Double-blind Randomized Withdrawal Period) | Randomization, Week 44 | All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value. | units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Randomization in the EuroQol Questionnaire-5 Dimension (EQ-5D) Index Scores, Visual Analog Scale up to Week 44 (Double-blind Randomized Withdrawal Period) | Randomization, up to Week 44 | All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value. Last observation carried forward (LOCF) methodology was used. | units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Number of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) (Double-blind Randomized Withdrawal Period) | Randomization through Week 44 | All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value. | participants | NUMBER |
| SECONDARY | Change From Randomization in the Arizona Sexual Experiences (ASEX) Questionnaire at Week 44 (Double-blind Randomized Withdrawal Period) | Randomization, Week 44 | All randomized participants who have non-missing values at the time of randomization and at least one post-randomization value. | units on a scale | LEAST_SQUARES_MEAN |
1 to 10 of 29Source ClinicalTrials.gov
See all 29 outcomesResults by group114
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Meet Criteria for Re-emergence of Depressive Symptoms Estimated by Kaplan-Meier Product Limit Method (Double-blind Randomized Withdrawal Period) | LY2216684 + SSRI | 10.43 | percentage of participants | ||
| Percentage of Participants Who Meet Criteria for Re-emergence of Depressive Symptoms Estimated by Kaplan-Meier Product Limit Method (Double-blind Randomized Withdrawal Period) | Placebo + SSRI | 8.24 | percentage of participants | ||
| Percentage of Participants With Re-emergence of Depressive Symptoms (Double-blind Randomized Withdrawal Period) | LY2216684 + SSRI | 9.9 | percentage of participants | ||
| Percentage of Participants With Re-emergence of Depressive Symptoms (Double-blind Randomized Withdrawal Period) | Placebo + SSRI | 8.2 | percentage of participants | ||
| Change From Randomization in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Item Scores at Week 44 (Double-blind Randomized Withdrawal Period) | LY2216684 + SSRI | MADRS Total Score | 0.40 | Standard Error 0.33 | units on a scale |
| Change From Randomization in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Item Scores at Week 44 (Double-blind Randomized Withdrawal Period) | Placebo + SSRI | MADRS Total Score | 0.34 | Standard Error 0.33 | units on a scale |
| Change From Randomization in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Item Scores at Week 44 (Double-blind Randomized Withdrawal Period) | LY2216684 + SSRI | Item 1: Apparent Sadness | 0.09 | Standard Error 0.05 | units on a scale |
| Change From Randomization in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Item Scores at Week 44 (Double-blind Randomized Withdrawal Period) | Placebo + SSRI | Item 1: Apparent Sadness | 0.08 | Standard Error 0.05 | units on a scale |
| Change From Randomization in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Item Scores at Week 44 (Double-blind Randomized Withdrawal Period) | LY2216684 + SSRI | Item 2: Reported Sadness | 0.09 | Standard Error 0.06 | units on a scale |
| Change From Randomization in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Item Scores at Week 44 (Double-blind Randomized Withdrawal Period) | Placebo + SSRI | Item 2: Reported Sadness | 0.05 | Standard Error 0.06 | units on a scale |
1 to 10 of 114Source ClinicalTrials.gov
See all 114 results by groupParticipant flow52
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Acute Open-label (OL) Period | STARTED | LY2216684 + SSRI (Acute Open-label Period) | 1,249 | |
| Acute Open-label (OL) Period | STARTED | LY2216684 + SSRI (Stabilization Open-label Period) | 0 | |
| Acute Open-label (OL) Period | STARTED | LY2216684 + SSRI (Double-blind Randomized Withdrawal Period) | 0 | |
| Acute Open-label (OL) Period | STARTED | Placebo + SSRI (Double-blind Randomized Withdrawal Period) | 0 | |
| Acute Open-label (OL) Period | Entered Discontinuation (DC) Period | LY2216684 + SSRI (Acute Open-label Period) | 271 | |
| Acute Open-label (OL) Period | Entered Discontinuation (DC) Period | LY2216684 + SSRI (Stabilization Open-label Period) | 0 | |
| Acute Open-label (OL) Period | Entered Discontinuation (DC) Period | LY2216684 + SSRI (Double-blind Randomized Withdrawal Period) | 0 | |
| Acute Open-label (OL) Period | Entered Discontinuation (DC) Period | Placebo + SSRI (Double-blind Randomized Withdrawal Period) | 0 | |
| Acute Open-label (OL) Period | COMPLETED | LY2216684 + SSRI (Acute Open-label Period) | 835 | |
| Acute Open-label (OL) Period | COMPLETED | LY2216684 + SSRI (Stabilization Open-label Period) | 0 |
1 to 10 of 52Source ClinicalTrials.gov
See all 52 participant flowAdverse events432
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Constipation | Gastrointestinal disorders | LY2216684 + SSRI (Acute Open-label Period) | 132 | 1,244 | 134 |
| other | Constipation | Gastrointestinal disorders | LY2216684 + SSRI (Stabilization Open-label Period) | 14 | 831 | 14 |
| other | Constipation | Gastrointestinal disorders | LY2216684 + SSRI (Double-blind Randomized Withdrawal Period) | 4 | 294 | 5 |
| other | Constipation | Gastrointestinal disorders | Placebo + SSRI (Double-blind Randomized Withdrawal Period) | 2 | 292 | 2 |
| other | Constipation | Gastrointestinal disorders | LY2216684 + SSRI (Randomized Tapered Discontinuation Period) | 0 | 128 | 0 |
| other | Constipation | Gastrointestinal disorders | LY2216684 + SSRI (Randomized Abrupt Discontinuation Period) | 0 | 132 | 0 |
| other | Constipation | Gastrointestinal disorders | Placebo + SSRI (Abrupt Discontinuation Period) | 0 | 267 | 0 |
| other | Constipation | Gastrointestinal disorders | LY2216684 + SSRI (Nonrandomized Abrupt Discontinuation Period) | 0 | 434 | 0 |
| other | Dry mouth | Gastrointestinal disorders | LY2216684 + SSRI (Acute Open-label Period) | 80 | 1,244 | 81 |
| other | Dry mouth | Gastrointestinal disorders | LY2216684 + SSRI (Stabilization Open-label Period) | 10 | 831 | 10 |
1 to 10 of 432Source ClinicalTrials.gov
See all 432 adverse eventsAdverse event totals24
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | LY2216684 + SSRI (Acute Open-label Period) | ||
| Total, all-cause mortality | LY2216684 + SSRI (Stabilization Open-label Period) | ||
| Total, all-cause mortality | LY2216684 + SSRI (Double-blind Randomized Withdrawal Period) | ||
| Total, all-cause mortality | Placebo + SSRI (Double-blind Randomized Withdrawal Period) | ||
| Total, all-cause mortality | LY2216684 + SSRI (Randomized Tapered Discontinuation Period) | ||
| Total, all-cause mortality | LY2216684 + SSRI (Randomized Abrupt Discontinuation Period) | ||
| Total, all-cause mortality | Placebo + SSRI (Abrupt Discontinuation Period) | ||
| Total, all-cause mortality | LY2216684 + SSRI (Nonrandomized Abrupt Discontinuation Period) | ||
| Total, other adverse events | LY2216684 + SSRI (Acute Open-label Period) | 505 | 1,244 |
| Total, other adverse events | LY2216684 + SSRI (Stabilization Open-label Period) | 112 | 831 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 adverse event totalsPapers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 25894953 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01299272
GET https://conductscience.org/api/trials/v1/NCT01299272/registered?page=2